Edition:
United States

Halozyme Therapeutics Inc (HALO.OQ)

HALO.OQ on NASDAQ Stock Exchange Global Select Market

19.87USD
23 Feb 2018
Change (% chg)

$0.59 (+3.06%)
Prev Close
$19.28
Open
$19.38
Day's High
$19.98
Day's Low
$19.31
Volume
493,702
Avg. Vol
375,709
52-wk High
$21.12
52-wk Low
$11.43

Latest Key Developments (Source: Significant Developments)

Halozyme Reports Q4 Earnings Per Share $0.85
Tuesday, 20 Feb 2018 04:05pm EST 

Feb 20 (Reuters) - Halozyme Therapeutics Inc ::HALOZYME REPORTS FOURTH QUARTER AND FULL-YEAR 2017 RESULTS.Q4 EARNINGS PER SHARE $0.85.Q4 REVENUE $189.6 MILLION VERSUS $39 MILLION.REITERATED 2018 FINANCIAL GUIDANCE FOR NET REVENUE OF $115 MILLION TO $125 MILLION.  Full Article

Halozyme Projects 25 To 30 Percent Enhanze Royalty Growth In 2018
Tuesday, 9 Jan 2018 06:30pm EST 

Jan 9 (Reuters) - Halozyme Therapeutics Inc ::HALOZYME PROJECTS 25 TO 30 PERCENT ENHANZE ROYALTY GROWTH IN 2018.HALOZYME THERAPEUTICS INC - ‍ FORECASTS POTENTIAL ROYALTY REVENUE FOR ENHANZE TO REACH NEARLY $1 BILLION IN 2027 ​.HALOZYME THERAPEUTICS INC - ‍EXPECTS ADDITIONAL PARTNERS TO BEGIN THREE PHASE 1 STUDIES WITH NEW TARGETS FOR ENHANZE​ IN 2018.  Full Article

Halozyme reports Q3 EPS of $0.02
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Halozyme Therapeutics Inc :Halozyme reports third quarter 2017 results.Q3 earnings per share $0.02.Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.Q3 revenue $63.7 million versus i/b/e/s view $59 million.Sees FY 2017 ‍net revenue of $265 million to $280 million​.Qtrly ‍ cash, cash equivalents & marketable securities were $316.9 million at Sept. 30, 2017, versus $297.5 million at June 30, 2017​.  Full Article

Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex
Tuesday, 31 Oct 2017 08:30am EDT 

Oct 31 (Reuters) - Halozyme Therapeutics Inc :Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex with co's enhanze technology​.Halozyme Therapeutics Inc - will receive a $15 million milestone payment from Janssen following dosing of third patient in a phase 3 trial​.  Full Article

Halozyme licenses new Enhanze target for $30 mln upfront payment
Thursday, 14 Sep 2017 07:06am EDT 

Sept 14 (Reuters) - Halozyme Therapeutics Inc ::Halozyme licenses new enhanze target for $30 million upfront payment, future milestones and royalties.Halozyme therapeutics-co will receive initial $30 million with potential to earn additional payments of up to $160 million, subject to certain milestones​.Halozyme therapeutics-licensed its enhanze drug-delivery technology to roche for exclusive development of an undisclosed therapeutic target.  Full Article

Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology
Thursday, 14 Sep 2017 06:59am EDT 

Sept 14 (Reuters) - Bristol-Myers Squibb Co :Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology.Bristol-Myers Squibb Co - ‍Halozyme to receive $105 million upfront payment, plus future milestones and royalties​.Bristol-Myers Squibb Co - ‍Halozyme to receive $105 million upfront payment, plus future milestones and royalties​.Bristol-Myers Squibb Co - ‍provides Bristol-Myers Squibb access to enhanze technology for up to 11 targets​.Bristol-Myers Squibb Co - ‍collaboration may extend to a maximum of 11 targets​.Bristol-Myers Squibb Co - ‍for Bristol-Myers Squibb, transaction is expected to be dilutive to non-gaap earnings per share in 2017​.Bristol-Myers - ‍Halozyme has potential to earn milestone payments of upto $160 million for each nominated collaboration targets,additional milestone payments​.Bristol-Myers Squibb says ‍for co, deal is expected to be dilutive to non-GAAP earnings per share in 2017 and 2018 by approximately $0.01​.Bristol-Myers Squibb Co - ‍for co, deal is expected to be dilutive to non-GAAP earnings per share by about $0.05 in 2019​.  Full Article

Halozyme reports Q2 loss per share $0.23
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 9 (Reuters) - Halozyme Therapeutics Inc -:Halozyme reports second quarter 2017 results.Q2 loss per share $0.23.Q2 revenue $33.8 million versus I/B/E/S view $31.8 million.Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $115 million to $130 million.Halozyme Therapeutics Inc sees 2017 net revenue of $115 million to $130 million.Halozyme Therapeutics Inc sees 2017 operating cash burn of $75 million to $85 million.Halozyme Therapeutics Inc sees 2017 year-end cash balance of $245 million to $260 million.FY2017 revenue view $132.1 million -- Thomson Reuters I/B/E/S.  Full Article

Halozyme announces initiation of clinical trial collaboration
Thursday, 13 Jul 2017 08:30am EDT 

July 13 (Reuters) - Halozyme Therapeutics Inc ::Initiation of clinical trial collaboration evaluating Halozyme's pegph20 in combination with anti-PDL1 immunotherapy.Halozyme Therapeutics says combination will be tested in patients with previously treated metastatic pancreatic ductal adenocarcinoma.Says ‍study is sponsored by and funded by Genentech​.  Full Article

Halozyme Therapeutics, unit entered into first amendment to amended, restated lease with BMR-11388 Sorrento Valley Road
Wednesday, 5 Jul 2017 04:22pm EDT 

July 5 (Reuters) - Halozyme Therapeutics Inc ::Halozyme Therapeutics Inc - co, unit entered into a first amendment to amended and restated lease with bmr-11388 sorrento valley road lp.Halozyme Therapeutics Inc - co, unit also entered into a first amendment to lease with bmr-sorrento plaza llc - sec filing.Halozyme Therapeutics Inc - lease amendments effectively extend company's tenancy at these facilities for an additional five years.Halozyme Therapeutics Inc - 11388 lease amendment extension commences on January 15, 2018 and expires on january 14, 2023.  Full Article

Halozyme Therapeutics prices public offering of common stock
Thursday, 18 May 2017 09:30pm EDT 

May 18 (Reuters) - Halozyme Therapeutics Inc :Halozyme Therapeutics prices public offering of common stock.Priced previously announced underwritten public offering of 10 million shares of its common stock at $12.50 per share.  Full Article

BRIEF-Halozyme Reports Q4 Earnings Per Share $0.85

* REITERATED 2018 FINANCIAL GUIDANCE FOR NET REVENUE OF $115 MILLION TO $125 MILLION Source text for Eikon: Further company coverage: